Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 7/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirodomast SCHEMBL29385413 | 1.00 | FEN1 (0.52) | FEN1ALDH1A1KDM4EPDE4APDE4B | |
| Pirodomast SCHEMBL9488218 | 0.99 | FEN1 (0.51) | FEN1ALDH1A1KDM4EPDE4APDE4B | |
| SCHEMBL9629983 | 0.99 | FEN1 (0.51) | FEN1ALDH1A1KDM4EPDE4APDE4B | |
| Water SCHEMBL9629740 | 0.98 | FEN1 (0.50) | FEN1ALDH1A1KDM4EPDE4APDE4B | |
| SCHEMBL9629745 | 0.88 | FEN1 (0.48) | FEN1ALDH1A1KDM4EPDE4APDE4B | |
| Water SCHEMBL9629016 | 0.87 | FEN1 (0.47) | FEN1ALDH1A1KDM4EPDE4APDE4B | |
| Pirodomast SCHEMBL607268 | 0.87 | LOXL3 (0.43) | FEN1ALDH1A1KDM4EPDE4APDE4B | |
| Water SCHEMBL10427748 | 0.85 | MAPT (0.44) | FEN1ALDH1A1KDM4EPDE4BPDE4D | |
| Water SCHEMBL10582943 | 0.85 | FEN1 (0.46) | FEN1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL125349 | 0.82 | FEN1 (0.49) | FEN1ALDH1A1KDM4EPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103664804-B | Pirodomast analogue, preparation method and application thereof | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-102596202-B | Crystalline forms of pemirolast | CARDOZ AB | 2015-01-21 | — | — | CN | claimed |
| CN-103987704-A | Flavonoid compounds | CARDERO THERAPEUTICS INC | 2014-08-13 | — | — | CN | claimed |
| CN-103664804-A | Picotamide analogues as well as preparation method and application thereof | ANHUI UNIVERSITY OF CHINESE MEDICINE | 2014-03-26 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| CN-101711279-A | Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations | PORTOLA PHARM INC | 2010-05-19 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0232328-B1 | ZWITTERIONIC BICYCLIC COMPOUNDS AND THEIR SALTS, SOLVATES, HYDRATES AND ESTERS | SCHERING CORPORATION (US) | 1992-04-15 | — | — | EP | claimed |
| EP-0338010-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE | SCHERING CORPORATION (US) | 1992-02-05 | — | — | EP | claimed |
| US-4684727-A | Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents | SCHERING CORPORATION (US) | 1987-08-04 | — | — | US | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-5079360-A | Processes for preparing bicyclic compounds and intermediates thereof | SCHERING CORPORATION (US) | 1992-01-07 | — | — | US | disclosed |
| US-4897487-A | Process for preparing intermediates for pharmaceutically useful bicyclic compounds | SCHERING CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
| EP-0302303-A2 | Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation | SCHERING CORPORATION (US) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | FEN1 4024/4885ALDH1A1 683/4885KDM4E 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.